Article Text

Download PDFPDF
Clinical round-up
  1. Emily Chung1,
  2. Sophie Herbert2
  1. 1 Mortimer Market Centre, Sexual Health and HIV, London, UK
  2. 2 Genitourinary Medicine, Ashwood Centre, Kettering, UK
  1. Correspondence to Dr Emily Chung, Sexual Health and HIV, Mortimer Market Centre, London WC1E 6JB, UK; e.chung{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Nine-valent human papillomavirus (HPV) vaccination could potentially prevent 90% of cervical cancer

Quadrivalent (qHPV) and bivalent vaccines against HPV are now used widely. The nine-valent HPV (9vHPV) vaccine protects against HPV 6, 11, 16, 18 already contained in the qHPV but additionally five more types associated with cervical cancer: 31, 33, 45, 52 and 58.

This randomised controlled double-blind, efficacy and safety study1 of the 9vHPV vaccine was carried out in 18 countries. Inclusion criteria were: healthy women aged 16–26, no history of abnormal cervical cytology or biopsy and maximum of four lifetime sexual partners. 14 215 participants received three injections of 9vHPV vaccine or qHPV control at day 1 and months 2 and 6. Cervical cytology, labial, vulvar, perineal, perianal, endocervical and ectocervical swabs were taken and genital examinations were performed on day 1, months 7, 12 and every 6 months after up to month 54. Swabs were tested for nine HPV types above. Serum was taken on day 1 and at intervals to 60 months to assess serological response.

Primary …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.